#ClinicalPharmacology #Pharmacokinetics #PharmacyEducation #Pharmacotherapy #MedicalEducation To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in Sun Pharma joins semaglutide race with over 60% cheaper generic #Noveltreat (for weight-loss) will cost patients between Rs 3,490 and Rs 7,400, while #Sematrinity (for type-2 diabetes) monthly cost ranges between Rs 2,960 and Rs 4,790
GLP-1 therapy at DermaVue starts at 5,660 per month for semaglutide and 13,000 per month for Mounjaro (tirzepatide)
Providers must access 835s through a clearinghouse or view remittance advices in NaviNet
Check at baseline, 6-8 weeks after starting, after each 10-15 pounds of weight loss, every 3-4 months during active weight loss, and every 6 months after weight stabilization
